Expert CMC Consulting for Helper-Dependent Adenoviral Vectors

FREQUENTLY ASKED QUESTIONS

CMC Consulting for Helper-Dependent Adenoviral (AdV) Platforms

CELL & GENE | RNA | BIOLOGICS

What are the primary CMC challenges specific to helper-dependent adenoviral (AdV) vectors that differ from AAV platforms?

High-capacity, helper-dependent AdV platforms present unique manufacturing and analytical hurdles. The main challenge is ensuring complete removal of the helper virus during purification, as residual contamination poses a significant safety risk. The large particle size and complex capsid structure of AdV also demand specialized analytical methods for characterization, titer, and potency that are distinct from standard AAV assays.

How do you establish a regulatory-compliant analytical strategy for a novel AdV therapeutic targeting a rare disease?

A robust analytical strategy for AdV is built on a phase-appropriate framework that aligns with ICH, FDA, and EMA expectations. This involves developing and qualifying custom potency assays early, establishing orthogonal methods for vector titer and purity, and creating a comprehensive profile of product-related impurities. The objective is to build a data package that provides a clear line of sight from preclinical batches to the material used in first-in-human studies.

What is the most effective way to de-risk the path to an IND submission for a complex AdV gene therapy program?

Minimizing clinical risk for an AdV program requires integrating CMC development with preclinical translational services from the outset. A tailored strategy that anticipates immunogenicity, defines the required GxP toxicology studies, and establishes a scalable manufacturing process is a foundational component. This integrated approach supports an 18-24 month timeline to IND, backed by the deep experience of a team with a proven track record.

CMC Strategy for Helper-Dependent Adenoviral Platforms

High-capacity, helper-dependent adenoviral (AdV) vectors offer a significant advantage for next-generation therapies that require large or multiple transgene cassettes. Their capacity exceeds that of many other viral vector systems, enabling complex genetic payloads. This capability, however, introduces distinct Chemistry, Manufacturing, and Controls (CMC) challenges that demand a specialized development and analytics strategy.

The manufacturing process for helper-dependent AdV is inherently more complex than for single-plasmid AAV systems. The core technical objective is to produce high-titer vector preparations that are demonstrably free of replication-competent helper virus. Achieving this requires rigorous process development, multi-step purification protocols, and highly sensitive analytical assays to detect and quantify any residual helper virus.

A tailored, phase-appropriate CMC plan is necessary to navigate these complexities. Key considerations include:

Upstream Process Optimization: Developing robust and scalable cell culture and transfection/infection conditions to maximize vector yield while minimizing helper virus propagation.
Downstream Purification: Implementing chromatographic and filtration steps capable of efficiently separating the larger AdV particles from smaller helper viruses and other process-related impurities.
Analytical Characterization: Employing a suite of orthogonal analytical methods to fully characterize the vector, including particle concentration, genome titer, aggregate analysis, and comprehensive impurity profiling.
Potency Assay Development: Designing and validating a biologically relevant potency assay that accurately reflects the vector’s mechanism of action and is suitable for lot release under GxP conditions.

Our approach is built on decades of vectorology experience, providing a clear development roadmap. As one biotech collaborator noted, “We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our program transitioned without interruption to the Franklin Biolabs Research Vector Division. Franklin Biolabs is integral to our AAV-vector based gene therapy candidate development, and we hope to continue the collaboration for years to come.”

While Franklin Biolabs was formally launched in 2024, our founding scientific leadership and core team of principal scientists have achieved a 100% successful IND rate since 2019. This track record in navigating regulatory submissions for complex programs informs our CMC consulting, which is a core component of our Vector | CMC | Analytics Services.

Insights from preclinical programs using other viral vectors also shape our strategy. For example, understanding vector-induced immune responses is a primary consideration. Preclinical NHP studies have shown that transgene products can trigger immune-mediated toxicities, a finding that underscores the need for careful immunogenicity risk assessment for any viral vector platform (PMID: 37033976). This principle directly applies to AdV, guiding the design of IND-enabling toxicology studies to proactively identify and mitigate potential immune-related risks. Optimizing these processes is a key factor in managing program timelines and costs.